소아청소년에서 편두통 치료 약물 처방 현황
Medication Prescribing Status in Pediatric Patients with Migraine
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Migraine is one of the leading causes of poor quality of life and disability, and migraine incidences in pediatrics areincreasing. Proper medication is important for the preventive and acute treatment of migraine. This study aimed to identify thecurrent status of prescribed medication in pediatric patients with migraine. Methods: We used data from a sample of pediatric patientsfrom the Health Insurance Review and Assessment Service (HIRA-PPS-2018) and analyzed the status of prescription drugs andfrequency of visits to medical institutions with migraine diagnoses in pediatric patients. Results: A total of 12,228 pediatric patientsdiagnosed with migraine during 2018 were analyzed. Among these patients, 7,170 (58.64%) were girls and 9,510 (77.77%) wereadolescents. Additionally, 9,157 patients (74.89%) received acute treatment, and 592 patients (4.84%) received combination therapywith analgesics and triptans. Acetaminophen for acute treatment and flunarizine for preventive treatment were the most commonlyprescribed. In most children and adolescents, acute treatment drugs were prescribed for less than 14 days. Conclusion: Analgesics,such as acetaminophen or non-steroidal anti-inflammatory drugs, were prescribed frequently for acute treatment in pediatric patientswith migraine. The drug prescription duration was within the recommended range, indicating a low risk of overdose. For preventivetreatment, clinically studied medication for pediatric patients with migraine was used.
Abstract
Background: Migraine is one of the leading causes of poor quality of life and disability, and migraine incidences in pediatrics areincreasing. Proper medication is important for the preventive and acute treatment of migraine. This study aimed to identify thecurrent status of prescribed medication in pediatric patients with migraine. Methods: We used data from a sample of pediatric patientsfrom the Health Insurance Review and Assessment Service (HIRA-PPS-2018) and analyzed the status of prescription drugs andfrequency of visits to medical institutions with migraine diagnoses in pediatric patients. Results: A total of 12,228 pediatric patientsdiagnosed with migraine during 2018 were analyzed. Among these patients, 7,170 (58.64%) were girls and 9,510 (77.77%) wereadolescents. Additionally, 9,157 patients (74.89%) received acute treatment, and 592 patients (4.84%) received combination therapywith analgesics and triptans. Acetaminophen for acute treatment and flunarizine for preventive treatment were the most commonlyprescribed. In most children and adolescents, acute treatment drugs were prescribed for less than 14 days. Conclusion: Analgesics,such as acetaminophen or non-steroidal anti-inflammatory drugs, were prescribed frequently for acute treatment in pediatric patientswith migraine. The drug prescription duration was within the recommended range, indicating a low risk of overdose. For preventivetreatment, clinically studied medication for pediatric patients with migraine was used.
참고문헌 (32)
- Burch RC, "The prevalence and burden of migraine and severe headache in the United States : Updated statistics from government health surveillance studies", Headache, 55(1), pp.21~34 (2015)
- Smitherman TA, "The prevalence, impact, and treatment of migraine and severe headaches in the United States: A review of statistics from national surveillance studies", Headache, 53(3), pp.427~436 (2013)
- Ashina M, "Migraine", N Engl J Med, 383(19), pp.1866~1876 (2020)
- Mortimer MJ, "Epidemiology of headache and childhood migraine in an urban general practice using Ad Hoc, Vahlquist and IHS criteria", Dev Med Child Neurol, 34(12), pp.1095~1101 (1992)
- GBD 2016 Headache Collaborators, "Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016", Lancet Neurol, 17(11), pp.954~976 (2018)
- Rho YI, "Prevalence and clinical characteristics of primary headaches among school children in South Korea : a nationwide survey", Headache, 52(4), pp.592~599 (2012)
- Lipton RB, "Migraine prevalence, disease burden, and the need for preventative therapy", Neurology, 68(5), pp.343~349 (2007)
- Deubner DC, "An epidemiologic study of migraine and headache in 10-20 year olds", Headache, 17(4), pp.173~180 (1977)
- Lee LH, "Clinical and demographic characteristics of migraine in urban children", Headache, 37(5), pp.269~276 (1997)
- 이건희, "소아청소년 편두통 치료의 최신지견", 대한의사협회지, 60(2), pp.118~125 (2017), 대한의사협회[DOI]
- 은소희, "소아 및 청소년에서 두통의 원인과 치료", Clinical and Experimental Pediatrics, 49(4), pp.354~363 (2006), 대한소아청소년과학회
- Patniyot I, "Short-term treatment of migraine in children and adolescents", JAMA Pediatr, 174(8), pp.789~790 (2020)
- Oskoui M, "Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society", Neurology, 93(11), pp.487~499 (2019)
- Thorlund K, "Risk of medication overuse headache across classes of treatments for acute migraine", J Headache Pain, 17(1), pp.107~ (2016)
- Bigal ME, "Acute migraine medications and evolution from episodic to chronic migraine : a longitudinal population-based study", Headache, 48(8), pp.1157~1168 (2008)
- El-Chammas K, "Pharmacologic treatment of pediatric headaches : a meta-analysis", JAMA Pediatr, 167(3), pp.250~258 (2013)
- O'Brien HL, "Treating pediatric migraine : an expert opinion", Expert Opin Pharmacother, 13(7), pp.959~966 (2012)
- Shamliyan TA, "Episodic migraines in children : limited evidence on preventive pharmacological treatments", J Child Neurol, 28(10), pp.1320~1341 (2013)
- Hershey AD, "Effectiveness of amitriptyline in the prophylactic management of childhood headaches", Headache, 40(7), pp.539~549 (2000)
- Kim J, "Association between Gastrointestinal Diseases and Migraine", Int J Environ Res Public Health, 19(7), pp.4018~ (2022)
- Ho TW, "Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design", Cephalalgia, 32(10), pp.750~765 (2012)
- Lewis DW, "Efficacy of zolmitriptan nasal spray in adolescent migraine", Pediatrics, 120(2), pp.390~396 (2007)
- Lewis DW, "The pharmacological treatment options for pediatric migraine : An evidence-based appraisal", NeuroRx, 3(2), pp.181~191 (2006)
- Genizi J, "Migraine abortive treatment in children and adolescents in Israel", Sci Rep, 12(1), pp.7418~ (2022)
- Damen L, "Symptomatic treatment of migraine in children : A systematic review of medication trials", Pediatrics, 116(2), pp.295~302 (2005)
- Richer L, "Drugs for the acute treatment of migraine in children and adolescents", Cochrane Database Syst Rev, 4(4), pp.CD005220~ (2016)
- Ludvigsson J, "Propranolol used in prophylaxis of migraine in children", Acta Neurol Scand, 50(1), pp.109~115 (1974)
- Sorge F, "Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study", Cephalalgia, 8(1), pp.1~6 (1988)
- Forsythe WI, "Propanolol(‘Inderal’)in the treatment of childhood migraine", Dev Med Child Neurol, 26(6), pp.737~741 (1984)
- Powers SW, "Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine", N Engl J Med, 376(2), pp.115~124 (2017)
- Lewis D, "Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age", Pediatrics, 123(3), pp.924~934 (2009)
- Winner P, "Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial", Headache, 45(10), pp.1304~1312 (2005)